Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thyroid Neoplasms 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Endometrial Adenocarcinoma 1Carcinoma, Medullary 1

Interventions

Radiotherapy 9Radiosurgery 6Oxaliplatin 5Cisplatin 5Paclitaxel 4Capecitabine 4Leucovorin 3Irinotecan 3Fluorouracil 3Doxorubicin 3Docetaxel 3strontium chloride 2regorafenib 2pembrolizumab 2enzalutamide 2Zoledronic Acid 2Temozolomide 2Radiofrequency Ablation 2Mitomycin 2Methods 2Ifosfamide 2Gemcitabine 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Bleomycin 2Bevacizumab 2Analgesia 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neoplasm Metastasis × nintedanib × Clear all
NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡